Procter & Gamble (PG), Cleveland Clinic to Partner on Heart Disease Biomarker Development, Commercialization
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Cleveland Clinic Partnering With Procter & Gamble And Cleveland HeartLab To Advance Discovery In Heart Disease
August 20, 2015 10:34 AM EDTCLEVELAND, Aug. 20, 2015 /PRNewswire/ -- Cleveland Clinic is collaborating with Cleveland HeartLab and Procter & Gamble (NYSE: PG) to develop and commercialize a diagnostic and management solution for a heart disease biomarker recently discovered by researchers in Cleveland Clinic's Lerner Research and Heart & Vascular Institutes.
As part of the collaboration, Cleveland HeartLab will develop a diagnostic test to measure blood levels of TMAO, or Trimethylamine-N-oxide, a substance produced by gut bacteria and that is linked to heart disease. Meanwhile, Cleveland Clinic researchers will work with Cincinnati-based P&G to develop an... More
